Last Posted: Oct 04, 2019
- Developing a Clinico-Molecular Test for Individualized Treatment of Ovarian Cancer: The interplay of Precision Medicine Informatics with Clinical and Health Economics Dimensions.
Winterhoff Boris et al. AMIA ... Annual Symposium proceedings. AMIA Symposium 2018 20181093-1102 - Value of the Rare Disease Registry of the Italian Region Friuli Venezia Giulia.
Valent Francesca et al. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2019 Sep 22(9) 1003-1011 - Application of Economic Evaluation to Assess Feasibility for Reimbursement of Genomic Testing as Part of Personalized Medicine Interventions.
Simeonidis Stavros et al. Frontiers in pharmacology 2019 10830 - Analytic Considerations in Applying a General Economic Evaluation Reference Case to Gene Therapy.
Drummond Michael F et al. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2019 22(6) 661-668 - Are Payers Ready, Willing, and Able to Provide Access to New Durable Gene Therapies?
Barlow Jane F et al. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2019 22(6) 642-647 - Health state utility values (QALY weights) for Huntington's disease: an analysis of data from the European Huntington's Disease Network (EHDN).
Hawton Annie et al. The European journal of health economics : HEPAC : health economics in prevention and care 2019 Aug - Is Genetic Exceptionalism Past Its Sell-By Date? On Genomic Diaries, Context, and Content.
Murray Thomas H et al. The American journal of bioethics : AJOB 2019 19(1) 13-15 - This Drug Will Save Children’s Lives. It Costs $2 Million.
NY Times editorial board, August 13, 2019 - Cost-Effectiveness Analysis of a HMGA2 Prognostic Test for Acute Myeloid Leukemia in a Canadian Setting.
Tremblay Gabriel et al. Applied health economics and health policy 2019 Aug - Clinical outcomes associated with pathogenic genomic instability mutations in prostate cancer: a retrospective analysis of US pharmacy and medical claims data.
Liu Jinan et al. Journal of medical economics 2019 Jul 1
No hay comentarios:
Publicar un comentario